1. 12LBA Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSe Program. Issue 3 (September 2015) Authors: Vassal, G.; Moro-sibilot, D.; Le Deley, M.C.; Hoog-labouret, N.; Nowak, F.; Jimenez, M.; Tournigand, C.; Houot, R.; Malka, D.; Aparicio, T.; Escudier, B.; Ray-coquard, I.; Godbert, Y.; Taillandier, L.; Bieche, I.; Lantuejoul, S.; Ferretti, G.; Menu, Y.; Blay, J.Y.; Buzyn, A. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2513 New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC). (September 2015) Authors: Derosa, L.; Guida, A.; Albiges, L.; Massard, C.; Loriot, Y.; Galli, L.; Fizazi, K.; Escudier, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S478 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2626 Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis. (September 2015) Authors: Guida, A.; Matias, M.; Albiges, L.; Derosa, L.; Loriot, Y.; Massard, C.; Fizazi, K.; Escudier, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S521 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (September 2015) Authors: Sharma, P.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; Castellano, D.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T.C.; Ueda, T.; Xu, L.A.; Waxman, I.M.; Motzer, R.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC). (September 2015) Authors: Oudard, S.; Benhamouda, N.; Escudier, B.; Ravel, P.; Kothari, D.; Mehmud, F.; Levionnois, E.; Sevin, E.; Negrier, S.; Barthelemy, P.; Berdah, J.F.; Ravaud, A.; Sternberg, C.N.; Bono, P.; Porta, C.; Giorgi, U. De; Parikh, O.; Hawkins, R.; Highley, M.; Tartour, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. (September 2015) Authors: Choueiri, T.; Escudier, B.; Powles, T.; Mainwaring, P.; Rini, B.; Donskov, F.; Hammers, H.; Hutson, T.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.; Schmidinger, M.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G.; Tannir, N.; Motzer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 603 Safety assessment of radiotherapy associated to targeted therapies in metastatic renal-cell carcinoma. (September 2015) Authors: Rivoirard, R.; Langrand-escure, J.; Vallard, A.; Mery, B.; Guy, J.B.; Espenel, S.; Trone, J.C.; Mrad, M. Ben; Diao, P.; Guillot, A.; Escudier, B.; Negrier, S.; Chargari, C.; Magne, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Checkpoint inhibitors in metastatic papillary renal cell carcinoma. (September 2021) Authors: de Vries-Brilland, M.; McDermott, D.F.; Suárez, C.; Powles, T.; Gross-Goupil, M.; Ravaud, A.; Flippot, R.; Escudier, B.; Albigès, L. Journal: Cancer treatment reviews Issue: Volume 99(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study. (February 2017) Authors: Grande, E.; Choueiri, T.K.; Motzer, R.J.; Escudier, B.; Pal, S.; Kollmannsberger, C.; Pikiel, J.; Gurney, H.; Rha, S.Y.; Park, S.H.; Geertsen, P.F.; Gross Goupil, M.; Suarez, C.; Arroyo, A.; Dean, M.; George, D.; Powles, T. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study. (February 2017) Authors: Bracarda, S.; Choueiri, T.K.; Powles, T.; Motzer, R.J.; Olencki, T.; Frontera, O.A.; Oudard, S.; Rolland, F.; Tomczak, P.; Castellano, D.; Appleman, L.; Drabkin, H.; Vaena, D.; Milwee, S.; Youkstetter, J.; Escudier, B. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗